--- title: "Maravai LifeSciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 65.84 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/285659018.md" datetime: "2026-05-08T03:38:48.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285659018.md) - [en](https://longbridge.com/en/news/285659018.md) - [zh-HK](https://longbridge.com/zh-HK/news/285659018.md) --- # Maravai LifeSciences | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 65.84 M Revenue: As of FY2026 Q1, the actual value is USD 65.84 M, beating the estimate of USD 53 M. EPS: As of FY2026 Q1, the actual value is USD -0.02, beating the estimate of USD -0.0875. EBIT: As of FY2026 Q1, the actual value is USD 1.718 M. Maravai LifeSciences Holdings, Inc. reported its financial results for the first quarter ended March 31, 2026, showing significant improvements across several metrics. #### Segment Revenue Total revenue for Q1 2026 was $65,837 thousand, marking a 40.5% year-over-year increase from $46,850 thousand in Q1 2025. The TRILINK segment revenue reached $47,476 thousand for Q1 2026, growing by 65.1% year-over-year from $28,750 thousand in Q1 2025, primarily due to $14.3 million in high-volume CleanCap orders for commercial phase COVID vaccine programs. Excluding COVID CleanCap revenue, TriLink base revenue increased by 15.4% year-over-year. The CYGNUS segment revenue was $18,361 thousand for Q1 2026, a 1.4% year-over-year increase from $18,100 thousand in Q1 2025, driven by strong demand in North America and EMEA, partially offset by lower contribution from China. #### Operational Metrics Net loss for Q1 2026 was - $6,377 thousand, a substantial improvement from - $52,853 thousand in Q1 2025. Net loss attributable to Maravai LifeSciences Holdings, Inc. was - $3,733 thousand for Q1 2026, compared to - $29,945 thousand for Q1 2025. Adjusted EBITDA (non-GAAP) was $20,327 thousand for Q1 2026, a significant increase from - $10,549 thousand for Q1 2025. Gross profit rose to $33,701 thousand for Q1 2026, up from $7,725 thousand for Q1 2025. Loss from operations improved to - $2,158 thousand for Q1 2026, compared to - $49,162 thousand for Q1 2025. Total operating expenses decreased to $35,859 thousand for Q1 2026 from $56,887 thousand for Q1 2025. Selling, general and administrative expenses were $29,092 thousand for Q1 2026, compared to $39,564 thousand for Q1 2025, while research and development expenses were $3,889 thousand for Q1 2026, down from $4,888 thousand for Q1 2025. Restructuring costs were $2,878 thousand for Q1 2026, and goodwill impairment was - $0 for Q1 2026, a notable change from $12,435 thousand for Q1 2025. Adjusted Net Income (Loss) (non-GAAP) was $3,837 thousand for Q1 2026, compared to - $20,436 thousand for Q1 2025. #### Cash Flow Net cash provided by operating activities was $8,665 thousand for Q1 2026, a positive shift from net cash used in operating activities of - $9,390 thousand for Q1 2025. Purchases of property and equipment amounted to - $4,437 thousand for Q1 2026, compared to - $4,501 thousand for Q1 2025. Free cash flow (non-GAAP) returned to positive at $4,228 thousand for Q1 2026, significantly improving from - $13,891 thousand for Q1 2025. #### Unique Metrics Base revenue, excluding high-volume CleanCap for commercialized COVID-19 vaccines, was up 10% from the prior year. TriLink Base, Non-COVID Revenue grew 15% year over year. #### Outlook / Guidance Maravai LifeSciences Holdings, Inc. increased its full-year 2026 guidance for both revenue and Adjusted EBITDA (non-GAAP). Revenue is now expected to be between $205.0 million and $215.0 million, up from the previous range of $200.0 million to $210.0 million. Adjusted EBITDA (non-GAAP) is projected to be between $30.0 million and $32.0 million, an increase from the prior range of $18.0 million to $20.0 million. ### Related Stocks - [MRVI.US](https://longbridge.com/en/quote/MRVI.US.md) ## Related News & Research - [Maravai LifeSciences To Attend The Jefferies Global Healthcare Conference | MRVI Stock News](https://longbridge.com/en/news/286812680.md) - [Capital City Bank Group posts Q1 2026 investor presentation on website](https://longbridge.com/en/news/286599786.md) - [FS KKR Capital to post investor presentations on website after market close](https://longbridge.com/en/news/286815114.md) - [Apollo Clarifies Legal Status of Recent 8-K Disclosure](https://longbridge.com/en/news/286564452.md) - [Current account deficit to widen to 2.3% of GDP in FY27 from 0.9% in FY26](https://longbridge.com/en/news/286766187.md)